AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer
Authors: Buller, RE Lallas, TA Shahin, MS Sood, AK Hatterman-Zogg, M Anderson, B Sorosky, JI Kirby, PA
Citation: Re. Buller et al., The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer, CLIN CANC R, 7(4), 2001, pp. 831-838
Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP)
Authors: Geisler, JR Hatterman-Zogg, MA Rathe, JA Lallas, TA Kirby, P Buller, RE
Citation: Jr. Geisler et al., Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP), HUM MUTAT, 18(4), 2001, pp. 337-344
Simultaneously detected endometrial and ovarian carcinomas - A prospectiveclinicopathologic study of 74 cases: A gynecologic oncology group study
Authors: Zaino, R Whitney, C Brady, MF DeGeest, K Burger, RA Buller, RE
Citation: R. Zaino et al., Simultaneously detected endometrial and ovarian carcinomas - A prospectiveclinicopathologic study of 74 cases: A gynecologic oncology group study, GYNECOL ONC, 83(2), 2001, pp. 355-362
Ovarian function after surgical treatment for cervical cancer
Authors: Buekers, TE Anderson, B Sorosky, JI Buller, RE
Citation: Te. Buekers et al., Ovarian function after surgical treatment for cervical cancer, GYNECOL ONC, 80(1), 2001, pp. 85-88
The androgen receptor and DXS15-134 markers show a high rate of discordance for germline X chromosome inactivation
Authors: Mahavni, V Kim, SC Benda, TA Sanders, L Buller, RE
Citation: V. Mahavni et al., The androgen receptor and DXS15-134 markers show a high rate of discordance for germline X chromosome inactivation, J MED GENET, 38(7), 2001, pp. 474-478
Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer
Authors: Sood, AK Holmes, R Hendrix, MJC Buller, RE
Citation: Ak. Sood et al., Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer, CANCER RES, 61(11), 2001, pp. 4371-4374
Molecular determinants of ovarian cancer plasticity
Authors: Sood, AK Seftor, EA Fletcher, MS Gardner, LMG Heidger, PM Buller, RE Seftor, REB Hendrix, MJC
Citation: Ak. Sood et al., Molecular determinants of ovarian cancer plasticity, AM J PATH, 158(4), 2001, pp. 1279-1288
p53 mutations and microsatellite instability in ovarian cancer: Yin and Yang
Authors: Buller, RE Shahin, MS Holmes, RW Hatterman, M Kirby, PA Sood, AK
Citation: Re. Buller et al., p53 mutations and microsatellite instability in ovarian cancer: Yin and Yang, AM J OBST G, 184(5), 2001, pp. 891-902
Longterm central venous access in gynecologic cancer patients
Authors: Minassian, VA Sood, AK Lowe, P Sorosky, JI Al-Jurf, AS Buller, RE
Citation: Va. Minassian et al., Longterm central venous access in gynecologic cancer patients, J AM COLL S, 191(4), 2000, pp. 403-409
Interleukin-6 and use of social support in gynecologic cancer patients
Authors: Lutgendorf, SK Anderson, B Sorosky, JI Buller, RE Lubaroff, DM
Citation: Sk. Lutgendorf et al., Interleukin-6 and use of social support in gynecologic cancer patients, INT J BEH M, 7(2), 2000, pp. 127-142
The glutathione S-transferase M1 genotype in ovarian cancer
Authors: Lallas, TA McClain, SK Shahin, MS Buller, RE
Citation: Ta. Lallas et al., The glutathione S-transferase M1 genotype in ovarian cancer, CANC EPID B, 9(6), 2000, pp. 587-590
BRCA1: What do we know? What do we think we know? What do we really need to know?
Authors: Buller, RE
Citation: Re. Buller, BRCA1: What do we know? What do we think we know? What do we really need to know?, GYNECOL ONC, 76(3), 2000, pp. 291-293
Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutationin ovarian cancer
Authors: Buekers, TE Lallas, TA Buller, RE
Citation: Te. Buekers et al., Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutationin ovarian cancer, GYNECOL ONC, 76(3), 2000, pp. 418-422
Cervical cancer diagnosed shortly after pregnancy: Prognostic variables and delivery routes
Authors: Sood, AK Sorosky, JI Mayr, N Anderson, B Buller, RE Niebyl, J
Citation: Ak. Sood et al., Cervical cancer diagnosed shortly after pregnancy: Prognostic variables and delivery routes, OBSTET GYN, 95(6), 2000, pp. 832-838
Computed tomography in endometrial carcinoma
Authors: Connor, JP Andrews, JI Anderson, B Buller, RE
Citation: Jp. Connor et al., Computed tomography in endometrial carcinoma, OBSTET GYN, 95(5), 2000, pp. 692-696
The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma
Authors: Shahin, MS Hughes, JH Sood, AK Buller, RE
Citation: Ms. Shahin et al., The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma, CANCER, 89(9), 2000, pp. 2006-2017
Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva
Authors: Zhang, SH Sood, AK Sorosky, JI Anderson, B Buller, RE
Citation: Sh. Zhang et al., Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva, CANCER, 89(7), 2000, pp. 1520-1525
Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer
Authors: Lutgendorf, SK Anderson, B Rothrock, N Buller, RE Sood, AK Sorosky, JI
Citation: Sk. Lutgendorf et al., Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer, CANCER, 89(6), 2000, pp. 1402-1411
SSCP and sequence analysis of p53 mutations in ovarian tumors
Authors: Sood, AK Buller, RE
Citation: Ak. Sood et Re. Buller, SSCP and sequence analysis of p53 mutations in ovarian tumors, METH MOL M, 39, 2000, pp. 323-328
Association between nonrandom X-chromosome inactivation and BRCA1 mutationin germline DNA of patients with ovarian cancer
Authors: Buller, RE Sood, AK Lallas, T Buekers, T Skilling, JS
Citation: Re. Buller et al., Association between nonrandom X-chromosome inactivation and BRCA1 mutationin germline DNA of patients with ovarian cancer, J NAT CANC, 91(4), 1999, pp. 339-346
Association between nonrandom X-chromosome inactivation and BRCA1 mutationin germline DNA of patients with ovarian cancer - Response
Authors: Buller, RE Sood, AK Lallas, T Buekers, T Skilling, JS
Citation: Re. Buller et al., Association between nonrandom X-chromosome inactivation and BRCA1 mutationin germline DNA of patients with ovarian cancer - Response, J NAT CANC, 91(17), 1999, pp. 1508-1509
BRCA1 mutations in familial ovarian cancer
Authors: Lallas, TA Buekers, TE Buller, RE
Citation: Ta. Lallas et al., BRCA1 mutations in familial ovarian cancer, MOL GEN MET, 67(4), 1999, pp. 357-363
Distant metastases in ovarian cancer: Association with p53 mutations
Authors: Sood, AK Sorosky, JI Dolan, M Anderson, B Buller, RE
Citation: Ak. Sood et al., Distant metastases in ovarian cancer: Association with p53 mutations, CLIN CANC R, 5(9), 1999, pp. 2485-2490
Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group
Authors: Moore, DH Blessing, JA Dunton, C Buller, RE Reid, GC
Citation: Dh. Moore et al., Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group, GYNECOL ONC, 75(3), 1999, pp. 473-475
Estrogen replacement therapy in endometrial and breast cancer survivors
Authors: Mahavni, V Buller, RE
Citation: V. Mahavni et Re. Buller, Estrogen replacement therapy in endometrial and breast cancer survivors, CLIN O GYNE, 42(4), 1999, pp. 863-875
Risultati: 1-25 | 26-26